- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Menu
Therapeutic Ramucirumab antibody from the original Cyramza® commercial drug.
Showing all 6 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
|---|---|---|---|---|---|---|---|---|---|---|
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.03 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.06 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.08 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.01 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.12 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
2020.06 |
182,70 € |
| Drug name | Cyramza® |
| INN | Ramucirumab |
| API type | Ramucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology. |
| Pharmacotherapeutic group | Antineoplastic agents, monoclonal antibodies |
| ATC code | L01XC21 |
| Target of antibody | VEGFR2; Synonyms: CD309, FLK1, VEGFR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09 |
| General function | |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components, including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and migration of human endothelial cells. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | |
| Original license holder | |
| Marketing authorisation numbers | EU/1/14/957/001 - 003 |
| Marketing authorisation holder | Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands |
| Name of the manufacturer of the biological active substance | ImClone Systems LLC 33 ImClone Drive, Branchburg New Jersey NJ 08876 UNITED STATES Eli Lilly S.A. Dunderrow Kinsale County Cork Ireland |
| Name and address of the manufacturer(s) responsible for batch release | Lilly, S.A. Avda de la Industria, 30 Alcobendas 28108 Madrid Spain |
| Max shelf life | 36 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Histidine Histidine monohydrochloride Sodium chloride Glycine (E640) Polysorbate 80 (E433) Water for injections |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
